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Abstract
The gut microbiota is increasingly considered as a symbiotic partner for the maintenance of health. The
homeostasis of the gut microbiota is dependent on host characteristics (age, gender, genetic background…),
environmental conditions (stress, drugs, gastrointestinal surgery, infectious and toxic agents…). Moreover, it is
dependent on the day-to-day dietary changes. Experimental data in animals, but also observational studies in
obese patients, suggest that the composition of the gut microbiota is a factor characterizing obese versus lean
individuals, diabetic versus non diabetic patients, or patients presenting hepatic diseases such as non alcoholic
steatohepatitis. Interestingly, the changes in the gut microbes can be reversed by dieting and related weight loss.
The qualitative and quantitative changes in the intake of specific food components (fatty acids, carbohydrates,
micronutrients, prebiotics, probiotics), have not only consequences on the gut microbiota composition, but may
modulate the expression of genes in host tissues such as the liver, adipose tissue, intestine, muscle. This in turn
may drive or lessen the development of fat mass and metabolic disturbances associated with the gut barrier
function and the systemic immunity. The relevance of the prebiotic or probiotic approaches in the management of
obesity in humans is supported by few intervention studies in humans up to now, but the experimental data
obtained with those compounds help to elucidate novel potential molecular targets relating diet with gut
microbes. The metagenomic and integrative metabolomic approaches could help elucidate which bacteria, among
the trillions in human gut, or more specifically which activities/genes, could participate to the control of host
energy metabolism, and could be relevant for future therapeutic developments.
Introduction
Overweight and obesity have reached epidemic levels. In
2008, 1,5 billion adults were overweight and over 200
million men and nearly 300 million women were obese.
Worldwide obesity has more than doubled since 1980.
Overweight and obesity are defined as an excess of fat
mass but is often assessed by the calculation of the body
mass index (BMI), calculated by dividing the weight (in
kg) by the size
2 (in meter
2). Subjects with a BMI greater
than or equal to 25 or 30 kg/m
2, are considered as over-
weight and obese, respectively. [1].
Obesity is associated with a cluster of metabolic disor-
ders such as insulin resistance, type 2 diabetes, fatty
liver disease, atherosclerosis, hypertension and stroke
but also with cancer, asthma, sleep apnoea, osteoarthri-
tis, neuro-degeneration, and gall-bladder disease [2].
The factors included in the definition of the metabolic
syndrome are dysglycemia, raised blood pressure, ele-
vated triglyceride levels, low high-density lipoprotein
cholesterol levels and obesity (particularly central adip-
osity). The presence of any three of these five risk fac-
tors constitutes a diagnosis of metabolic syndrome [3].
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ance resulting from an increased energy intake from the
diet and a decreased energy output associated i.e., with
low physical activity. In addition, the genetic back-
ground participates to the inter-individual difference in
term of energy expenditure and storage capacity. How-
ever, growing evidence suggests that among the “exter-
nal” factors contributing to the host response towards
nutrients, the gut microbiota represents an important
one. We are harbouring 10
14 bacteria in our gut; the gut
microbiome (microbial genome) represents therefore
150 fold more gene than the human genome, and the
metabolic potential of the gut microbiota, analysed for
example in the European MetaHit project, is tremen-
dous [4,5]. Even if most of the functions of the micro-
bial genes are still unknown, and if we are conditioned
at birth with a “personal” profile of gut microbes,
experiments performed in a model of mice colonized
with the human gut microbiota revealed that changes in
the diet composition (from high carbohydrates to wes-
tern diet which caused the mice to become obese)
allowed a rapid switch of the microbial community [6].
Interestingly, this modified gut microbiota could be
transferred to germ free mice concomitantly with the
obese phenotype [6]. Those data suggest, as illustrated
in figure 1, that the gut microbiota composition/activity
is a factor to take into account when assessing the risk
factors related to obesity, but also to associated diseases,
such dyslipidemia and atherosclerosis, insulin resistance
and diabetes, hepatic steatosis and steatohepatitis
[5,7-10].
The purpose of this review is to present the underly-
ing mechanisms by which nutrients and food compo-
nents which target the gut microbiota may play a role in
the management of obesity and metabolic syndrome.
This paper will mostly focus on the data relating the
effect of non digestible carbohydrates exhibiting prebio-
tic properties, such as dietary fructans.
Gut microbiota composition and metabolism
associated with the metabolic disorders in obese
individuals
The gut microbiota present particular genetic and meta-
bolic attributes, thereby giving the host the potential to
Figure 1 Obesity and related metabolic diseases: which role for the gut microbiota? In several organs and in the serum, lipid
accumulation and pro-inflammatory processes contribute to metabolic alterations leading to an increased risk of cardiovascular disease, diabetes
and non alcoholic steato-hepatitis. The production of metabolites and cytokines by the adipose tissue is playing a crucial role. A novel partner to
consider would be the gut microbiota which could, depending on its composition and activity, either positively or negatively contribute to
metabolic syndrome. NASH, Non-Alcoholic SteatoHepatitis
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ten fold more numerous than the number of cells in the
human body [8,11-13].
Novel culture-independent technologies based on the
analysis of the bacterial 16S rRNA gene (e.g., pyrose-
quensing) allowed significant progress in the knowledge
of our microbial partners with which we live in symbio-
sis [14,15]. Most of the studies concerning the relation
between host phenotype involving obesity and/or dia-
betes and gut microbiota, report changes of the relative
abundance of phyla, gender, or species of bacteria,
which correlate – positively or negatively- with biomar-
kers of the disease measured in the host (body mass
index, glycemia, pro-inflammatory cytokines….) [10,16].
The first study describing qualitative changes of the gut
microbiota in human obese individuals was published a
few years ago [17]. In this study, the analysis of fecal
samples of obese versus matched lean individuals
showed a shift in bacterial phyla (lower Bacteroidetes
and more Firmicutes) [17]. Interestingly, the authors
observed that after weight loss (following a fat restricted
or a carbohydrate restricted low calorie diet), the ratio
of Bacteroidetes to Firmicutes approached a lean type
profile after 52 weeks [17]. The focus on Bacteroidetes
seems to be controversial. A reduction of Bacteroidetes
community in obese patients was confirmed later [18].
In another study, no differences were detected between
obese and non-obese individuals in term of the propor-
tion of Bacteroidetes measured in the fecal samples, and
no significant changes of the percentage of Bacteroidetes
occurred in feces from obese subjects upon weight loss
[19]. In accordance with these data, even more Bacteroi-
detes were detected in a group of obese subjects than in
normal-weight individuals [20]. A subgroup of Bacteroi-
detes (Prevotellaceae) was significantly enriched in the
obese individuals. Moreover, the same authors showed
that surgical treatment for morbid obesity (gastric
bypass) strongly increased Gammaproteobacteria (mem-
bers of the family Enterobacteriaceae) and proportionally
decreased Firmicutes [20]. The methodology used for
bacterial analysis could explain certain discrepancies
between results published by different groups [21].
Recently, three robust clusters referred to as “entero-
types” have been identified in individuals from different
countries and a continent [22]. They found that these
enterotypes were identified by the variation at the level
of one of the three following genera : Bacteroides, Prevo-
tella and Ruminococcus. It is important to note that
these enterotypes were not correlated with the host
characteristics such as body mass index (BMI), age, gen-
der or nationality. Importantly, this large study did not
revealed any correlation between BMI and Firmicutes/
Bacteroidetes ratio [22]. However, although no differ-
ence in the microbiota composition has been described,
a set of 3 genes modules have been strongly correlated
with the host’s BMI, two of which are ATPase com-
plexes, supporting the link found between the gut
microbiota’s capacity for energy harvest and obesity in
the host [22].
The hypothesis of more specific modulation of the gut
microbiota community in obesity (instead of those
obtained at the wide phylum levels) is supported by sev-
eral studies. Bifidobacterium spp. number was higher in
children who exhibited a normal weight at 7 years than
in children developing overweight [23]. More impor-
tantly they observed that the Staphylococcus aureus
levels were lower in children who maintain a normal
weight than in children becoming overweight several
years later. The authors proposed that S. aureus may act
as a trigger of low-grade inflammation [24], contributing
to the development of obesity [25]. In agreement with
these last findings, significant differences have been
observed in gut microbiota composition according to
the body weight gain during pregnancy [26]. Interest-
ingly, the authors found significantly higher numbers of
Bacteroides group in women with excessive weight gain
upon pregnancy. They also established a positive corre-
lation between the number of Bacteroides, Clostridium
and Staphylococcus on the one hand, and the weight
and BMI before pregnancy, on the other hand. The Bifi-
dobacterium genus was present in higher numbers in
normal-weight than in overweight women and also in
women with lower weight gain during pregnancy [26].
The Bifidobacterium genus was also poorly represented
in the fecal samples of diabetic patients compared with
healthy individuals [27]. Nevertheless, a recent report
has shown that weight loss could also be associated with
reduced level of Bifidobacterium bifidum and Bifidobac-
terium breve counts and increased Bifidobacterium cate-
nulatum[28]. The level of Bifidobacterium g e n u si sa l s o
decreased upon weight loss after bariatric surgery per-
formed in obese individuals [29]. Indeed, Bifidobacter-
ium spp. represent an important and complex group of
bacteria whose presence is often associated with benefi-
cial health effects [30-32]. Another interesting bacterial
species is Faecalibacterium prausnitzii,w h o s el e v e li s
decreased in subjects with diabetes versus non diabetic
obese, and which is associated negatively with inflamma-
tory markers measured in the serum of obese indivi-
duals before and after roux- and Y gastric bypass
surgery [29].
Other selective changes of bacterial composition have
been described in obese human individuals, for which
the relation with fat mass are sometimes controversial.
Lactobacilli counts were higher in 8 out of 20 obese
patients compared to the number measured in lean indi-
viduals (detected in only 1 out of 20) [18]. Paradoxically,
the weight loss due to calorie restriction and physical
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cilli [28]. The focus on lactobacilli level may come from
the fact that they are part of the Firmicutes phyla,
which is increased upon obesity in most of the pub-
lished studies. It seems, however, that the targeted pro-
biotic approach with specific strains of Lactobacillus
does not increase, but even decreases the metabolic
alterations occurring in obesity, even if the number of
interventional studies in humans, reported until now,
remains low. The administration of Lactobacillus gasseri
has been shown to decrease fat mass (visceral and sub-
cutaneous) and body mass index in obese and type 2
diabetic patients [33]. The administration of Lactobacil-
lus spp. has been shown to positively impact on insulin
sensitivity [34]. They showed, in a double blind rando-
mised study performed in 45 male subjects with type 2
diabetes, impaired, or normal glucose tolerance, that the
administration of L. acidophilus NCFM for four weeks,
preserved the insulin sensitivity -assessed by an euglyce-
mic hyperinsulinemic clamp-, whereas it decreased in
the placebo group [34]. Finally, the early gut microbiota
modulation with probiotics (Lactobacillus rhamnosus
GG and Bifidobacterium lactis Bb12) reduced the body
mass index in young children by restraining excessive
weight gain during the first years of life (from 0 to 10
years of follow-up) [35]. The probiotic approach in
experimental studies in animals also suggests a decrease
in adiposity in different animal models of obesity. For
example, the treatment of high fat fed mice with specific
strains of Lactobacillus plantarum or Lactobacillus
paracasei spp paracasei reduced adipocyte cell size and
body fat [36,37]. More recently, it was shown that rats
fed with high-energy-dense diet at pregnancy, through-
out lactation and until 6 months of age, exhibited a
lower weight gain, and a lower retroperitoneal adipose
tissue when supplemented with Lactobacillus plan-
tarum, an effect not observed when treated with Escher-
ichia coli[38].
Those data suggest that specific changes in the gut
microbiota characterize the obese state and associated
metabolic diseases, including diabetes. However, we may
not conclude, from the papers published until now, that
targeting one specific bacterial target is sufficient to get
an improvement of a complex disease such as obesity.
Only few intervention studies have been performed with
selected probiotics, and this had never been performed
in order to counteract a drop in a specific “indigenous”
bacteria considered as beneficial.
Gut microbes/nutrients interactions: a way to
produce bioactive metabolites prone to interact
with host tissues
It is becoming feasible and relevant to focus on the
metabolic and functional properties of the gut
microbiota. This approach reveals, in certain studies,
that the changes in the gut microbiota composition
occurring in obese mice (ob/ob mice or high fat diet fed
mice) could be in favour of bacteria exhibiting saccharo-
lytic activities [39-41]. The studies performed in germ
free mice colonized with the caecal content obtained
from obese and insulin-resistant mice have shown that
the phenotype (obesity, insulin resistance and/or inflam-
mation) can be transferred to the germ-free recipient
through the microbial colonization, thereby suggesting
that some elements of the gut microbes drive metabolic
alterations in host tissues [40,42]. The experiments per-
formed on germ free mice colonized with gut microbes,
and then exposed to different types of diets, are illustrat-
ing the fact that the host response in term of fat mass
development depends on the interactions between gut
microbes and nutrients (for review, see [43]). Recently,
it has been shown in obese and lean human individuals
that the increase in calorie intake (from 2400 to 3400
kcal/d) promoted rapid changes in the gut microbiota
(20% increase in Firmicutes and a corresponding
decrease in Bacteroidetes). This was associated with an
increased energy harvest of ≈150 kcal, the overfeeding
in lean individuals being accompanied by a greater frac-
tional decrease in stool energy loss [44].
The promoting effect of the gut microbiota on intest-
inal glucose absorption has been suggested in germ free
mice colonized with the saccharolytic Bacteroides the-
taiotaomicron : this effect supports the fact that events
occurring upon bacterial fermentation may have an
effect in the upper part of the gut, and thereby affecting
digestible carbohydrates availability [45]. Conventionali-
zation of germ free mice has been demonstrated to pro-
mote body weight gain and fat mass development [46].
Interestingly, the conventionalization also brought about
a general increase in the activity of the enzyme lipopro-
tein lipase (LPL), catalyzing the release of fatty acids and
triacylglycerol from circulating lipoproteins in muscle,
and adipose tissue. The authors proposed that such an
increase was the consequence of suppression of the
Fasting-Induced Adipose Factor (FIAF) in the gut. Given
that FIAF inhibits the LPL activity, the blunted FIAF
expression in conventionalized germ free mice could
thus participate to the accumulation of lipids in the adi-
pose tissue [46]. In another set of experiment the
authors maintained germ free mice or conventionalized
mice on a high fat/high carbohydrates diet (western
d i e t ) .T h e yf o u n dt h a tg e r mf r e em i c ew e r er e s i s t a n tt o
the high-fat diet-induced body weight and fat mass gain
than the conventionalized mice [47]. This increase in fat
mass upon high fat diet feeding in conventionalized ver-
sus germ free animals, supports the fact that the fat sto-
rage is favoured by the presence of the gut microbiota
[46,47]. However, the observation of the metabolic
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nalized mice, suggest that the presence of carbohydrates
in the diet may modulate the development of obesity
upon colonization of the gut [48].
Just as the gut microbes influence the metabolic fea-
ture of nutrients, it is also clear that the ingestion of
specific nutrients play a role in the microbial changes.
We have previously demonstrated that diet-induced
obesity (high fat-low carbohydrates diet) in mice mark-
edly affects the gut microbial community whereby the
levels of Bifidibacterium spp. and E. rectale/Cl. coccoides
group were significantly reduced [25,49]. The effect of
feeding a high fat diet to conventional mice and RELMb
knock-out mice, the latter of which are resistant to fat-
induced obesity, resulted in a decrease in Bacteroidetes
and an increase in Firmicutes and Proteobacteria for
both genotypes, indicating that high fat diet itself rather
than the obese state may account for the changes in
microbiota composition [50].
Another bacterial element to take into account when
assessing the interaction between nutrients, gut microbes
and host health is microbial-related inflammation process
(for review, see de Lartigue et al [51]). The relationship
between the gut microbiota, impact of a high fat diet and
gut inflammation was investigated using germ-free mice
fed a high-fat diet [52]. The latter exhibited neither an
increase in TNFalpha mRNA nor activation of NF-Bi n
the ileum as compared to conventional mice, thereby sug-
gesting that both the combination of high-fat diet and the
presence of gut microbes are necessary to induce intestinal
inflammation [52]. More importantly, the development of
weight gain, adiposity, and plasma levels of insulin and
glucose were positively associated with intestinal inflam-
mation, further supporting the idea that intestinal inflam-
mation may be an early event by which fat diets contribute
or lead to the development of obesity and associated disor-
ders [52]. In addition, specific components of bacterial
membrane components have been implicated in the devel-
opment of inflammation upon obesity and diabetes. This
is the case of the lipopolysaccharides (LPS), the main com-
ponent of the gram negative bacteria (for review, see [8]).
The level of serum LPS is increased by about twice in
obese, diabetic, or high fat diet fed individuals, by pro-
cesses involving an increase in chylomicron (lipoproteins
that transport triglycerides and cholesterol from the small
intestine to other tissues) formation (upon high fat diet
feeding), a decrease in gut barrier integrity, and a decrease
in alkaline phosphatase activity, which is the enzyme
r e s p o n s i b l ef o rt h ec l e a v a g eo ft h eL P Si nt h ei n t e s t i n e .
Those metabolic alterations are illustrated in figure 2.
Other microbial derived elements play a role in the
regulation of host homeostasis. Nutrients which escape
the digestion to the upper part of the gut, are fermented
by gut microbes, which release namely short chain fatty
acids (SCFA) (acetate, propionate, butyrate). Those bac-
terial metabolites are absorbed by host intestinal tissue,
and thereby could participate to “energy harvest”.I n
addition, SCFA are able to act as signalling molecules in
host tissues, by linking selected G protein-coupled
receptors, free fatty acid receptors FFAR2 and FFAR3
[53]. In fact, FFAR3
-/- mice, which do not express the
receptor able to bind the SCFA, gain less weight when
colonized with saccharolytic bacteria (B. thetaiotaomi-
cron and M. smithii), as compared to mice expressing
the receptor [54]. This suggests that the SCFA may pro-
mote weight gain by binding to this receptor. Other
data have shown that SFCA (acetate, propionate) may
stimulate adipogenesis in the white adipose tissue via
FFAR2 activation [55].
These data suggest that the ingestion of fermentable
carbohydrates de facto contribute to an increase in fat
mass. Nevertheless, numerous other data obtained with
non digestible/highly fermentable carbohydrates with
prebiotic properties, counteract this hypothesis.
Interaction of prebiotic carbohydrates with host
energy metabolism
In different experimental models of obesity (ob/ob mice,
diet-induced obesity, obese Zucker rats), dietary supple-
mentation with non digestible/fermentable carbohy-
drates, such as inulin-type fructans or arabinoxylans,
exert beneficial effects for the host and can reduce adip-
o s i t y( s e er e v i e w ,[ 9 , 5 6 , 5 7 ] ) .D i e t a r yf r u c t a n sh a v eb e e n
more extensively studied as compared to other interest-
ing compounds with potential prebiotic properties
(galacto-oligosaccharides, xylooligosaccharides, lactulose)
up to now, namely in the context of obesity [58]. Treat-
ing obese individuals with fructans-type prebiotics has
been tried in a limited number of intervention studies.
Ingestion of inulin-type fructans prebiotic (8g/d) for one
year showed a significant benefit in the maintenance of
BMI, and fat mass in non obese young adolescents [59].
The daily intake of yacon syrup, which delivered 0.14g
fructans per kg per day over 120 days, increased satiety
sensation and decreased body weight, waist circumfer-
ence and body mass index in obese pre-menopausal
women [60]. Finally, a recent clinical trial, whereby
short chain inulin-type fructan were given as a supple-
ment for 3 months (21g/d), decreased food intake, body
weight gain and fat mass development in obese subjects,
which supports the evidence that prebiotics promote
weight maintenance [61]. The authors found higher
plasma PYY levels following a meal, as well as a drop in
ghrelin over a 6-hour meal tolerance test [61]. The
modulation of gut peptides by fructans-type prebiotics
(16g/d, two weeks) in healthy individuals also increased
GLP-1, PYY and GIP, an effect which correlates with a
decreased glycemic response, and a decrease in energy
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type fructans for 2 weeks [62]. In obese animal fed inu-
lin-type fructans (10% in the diet), a decrease in food
intake through the modulation of the production of gas-
tro-intestinal peptides also occurred, together with an
increase in anorexigenic peptides (PYY and GLP-1 (7-
36) amide) and a decrease in the orexigenic peptide
ghrelin. This lead us to postulate that the improvement
of obesity and related diseases by fermentable carbohy-
drates can be mediated through the modulation of the
endocrine function of the gut. In fact, an increase in the
number of L cells – linked to an increase in the differ-
entiation of those cells in the jejunum and in the colon
- is observed in rats and mice fed with inulin-type fruc-
tans prebiotics (for review, see [8]). By using models of
mice lacking a functional GLP-1 receptor, it was demon-
strated that the activation of the GLP-1 producing cells
in the gut drives the improvement of glycemic and insu-
lin response, lessens fat mass, and participates to the
satietogenic effect of the prebiotics. On the other hand,
the over-secretion of GLP-2 (co-secreted with GLP1 by
L cells) is implicated in the lower systemic inflammation
(decrease in circulating LPS and proinflammatory cyto-
kines) occurring in obese mice (Figure 3). The decrease
in LPS absorption through an improvement of the
expression and activity of proteins involved in gut bar-
rier function (Zonula-occludens 1 (ZO-1) and Occlu-
din), occurs in prebiotics treated animals (Figure 3).
Importantly, we found that changing the gut microbiota
with prebiotics promotes the normalisation of the endo-
cannabinoid system (eCB) responsiveness in the gut,
thereby decreasing in gut permeability, metabolic endo-
toxemia and fat mass development (Figure 3). However,
those effects are still unravelled in humans
[49,56,62-68]. The “anti-inflammatory” effect of prebio-
tics seems particularly interesting, since as illustrated
earlier, several studies suggest that the gut microbiota
c a nb ei n v o l v e di nt h ed e v e l o p m e n to fal o w - g r a d e
inflammation classically associated with the metabolic
disorders related to obesity [25][51,69].
Figure 2 Occurrence of entotoxemia upon high fat diet feeding and obesity. An increase level of lipopolysaccharides (LPS) characterizes
obese and diabetic individuals. This effect is mostly due to processes involving the transport of LPS from the gut to the blood, those processes
being an increase in chylomicron-driven transport of LPS, a rupture of the gut barrier integrity leading to abnormal gut permeability, and a
decrease in processes involved in intestinal LPS degradation (alkaline phosphatase activity). The increase in LPS (endotoxemia) thereby activates
the macrophages in the different tissues leading to a low tone inflammation involved in the metabolic alterations occurring upon obesity.
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species/phyla in the improvement of metabolic syn-
drome by fructans-type prebiotics is a matter of debate.
As previously described, several reports have shown that
obesity induced following dietary manipulations (high
fat feeding) or genetic deletion (leptin deficient models)
is characterized by changes in gut microbiota towards a
decreased number of bifidobacteria [70-75]. This group
of bacteria has been shown to reduce intestinal LPS
levels in mice and to improve the mucosal barrier func-
tion [25,40,49,76]. We can not preclude, in view of the
complexity of the gut microbiota, that bifidobacteria are
the sole actors in the improvement of metabolic disor-
ders associated with obesity by prebiotics. Other non
digestible/fermentable carbohydrates such as resistant
starch (type 4), are able to increase Actinobacteria and
specific types of bifidobacteria (Bifidobacterium adoles-
centis) in human individuals [77]. Those resistant
starches have also been proposed as nutrients able to
control glycemia and food intake by changing the profile
of gut hormones, such as GLP-1. However, there is no
proof until now that the increase in Bifidobacteria parti-
cipates per se to the increase in the endocrine function
of the gut upon prebiotics treatment.
In fact, we have recently studied the composition of the
gut microbiota using the pyrosequencing of the 16S rRNA
gene of the caecal content of ob/ob mice treated with
prebiotics, and we discovered more than a hundred
sequence which were different upon prebiotic treatment,
some of them being modified by more than ten fold, some
of them being correlated with the number of L cells in the
colon and the intestine (PD. Cani, personal
communication).
Altogether, those data imply that, if the gut microbial
activity is devoted to ferment carbohydrates, the energy
sparing due to the production of the short chain fatty
acids may be supplanted by other biochemical events
occurring in the gut upon the changes in the microbial
composition and/or activity. In fact, we have recently
shown upon fructans supplementation in high fat diet
fed mice, that the increase in fermentation occurring in
the caecum, leads to a decrease in the expression of the
genes responding to the short chain fatty acids (FFAR2)
in the adipose tissue , and thereby lessens the develop-
ment of fat mass [78]. Adaptive processes thus take
place far from the gut (for example in the liver and the
adipose tissue) upon prebiotic approach, which could
contribute to an improvement of metabolic syndrome.
Those effects are illustrated in figure 3.
Conclusion and perspectives
The elucidation of specific bacterial phyla/gender/spe-
cies whose number correlates with fat mass develop-
ment could help discovering a new type of “target” in
Figure 3 Improvement of obesity and related metabolic disorders by the prebiotic approach. Nutrients with prebiotic properties allows,
by changing the gut microbiota, to promote the endocrine function of the gut (increase in GLP-1, and GLP-2 producing cells), and to modulate
the activation of the endocannabinoid system in the intestine and in the adipose tissue. All those effects contribute to lessen gut permeability
(improved distribution of the tight junction proteins ZO-1 and Occludin), thereby decreasing endotoxemia, and systemic inflammation. Changes
in GLP-1 contribute to decrease food intake, fat mass, glycemia and insulin resistance. eCB, endocannabinoid; GLP-1, glucagon-like peptide 1;
GLP-2, glucagon-like peptide 2; LPS, lipopolysaccharides; ZO-1, zonula occludens 1.
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of the data published until now in humans, have ana-
lyzed fecal samples in order to relate the changes in gut
microbiota composition, obesity or food intake beha-
viour. In fact, the composition of the fecal microbiota
does not fully represent the microbial composition in
the colon. Moreover, recent data suggest that the
mucosa of proximal small intestine is highly responsive
to changes in the microbial composition driven by a
probiotic approach [79]. In addition, we have shown
that the modulation of the endocrine L cells number,
induced in mice by the prebiotic approach, is occurring
not only in the colon, but also in the jejunum. Finally,
the events linking the host microbes to diabetes would
also implicate the oral microbiota, which can be modi-
fied by prebiotics an probiotics [80,81]. All those data
suggest that, even if the vast majority of microbes reside
in the colon, one might also pay attention to microbial
modulation occurring in other body compartments in
order to understand how the interplay between nutri-
ents and gut microbes influences host health, namely in
the context of diabetes and obesity.
It is crucial to analyse the metabolic potential of the
gut microbes in totally in order to understand the bio-
chemical mechanism underlying the energy sparing or
energy expenditure due to nutrients/microbial interac-
tion. The saccharolytic activity of the gut microbiota,
namely through the production of short chain fatty
acids, has been proposed as a potential driver of adipo-
genesis. However, highly fermentable carbohydrates,
such as prebiotics, are able to counteract most of the
metabolic alterations linked to obesity, despite (or
thanks to?) the fact that they are actively fermented into
short chain fatty acids. It is likely that the targeted mod-
ification of the gut microbiota can also be obtained by
the administration of bacteria themselves. For example,
a targeted probiotic approach leading to the production
of bioactive lipids prone to regulate host homeostasis
(conjugated linoleic acids) are particularly interesting
[82]. Finally, we largely ignore if and how the host itself
may influence the composition of the gut microbiota,
and thereby take advantage of its symbiotic partner. We
have recently shown in mice deprived of dietary magne-
sium for 2 days that the magnesium deficiency pro-
moted systemic and intestinal inflammation just within
the two days [83]. However, those detrimental effects
were abolished after three weeks of magnesium-defi-
ciency, a phenomenon associated with specific changes
in gut microbiota composition in favour of bacteria rein-
forcing the gut barrier function (increased bifidobac-
teria) [83]. Therefore, it’s possible that not only
macronutrients, but also micronutrients and phytochem-
icals present in minor concentrations in the diet are
interacting with the gut microbes to modulate host
physiology. The relevance of this in the field of obesity
and associated metabolic disorders remains to be
unravelled.
The gut microbiota thus appears as an important tar-
get to consider in the management of obesity and
related diseases. The advantage of this target is that
both nutritional and pharmacological approaches will be
developed upon the increasing knowledge of host-
microbe interactions. The metabolomic approach will be
without any doubt, a way to understand how microbial
activities are related to host phenotype metabolism. The
metabolomic NMR analysis of different tissues and
fluids of conventional versus germ free mice allowed the
presence of a specific family of bacteria (Coriobacteria-
ceae family) to be linked with the regulation of hepatic
intermediary and xenobiotic metabolism [84]. Recently,
i tw a ss h o w nb yN M Ra n a l y s i so fb i o m a r k e r si nt h e
serum of genetically obese versus lean growing pigs that
changes in gut microbiota-related metabolites occurred,
including trimethylamine-N-oxide and choline, in addi-
tion to markers of lipogenesis, lipid oxidation, energy
utilization and partition, protein and amino acid meta-
bolism [85]. Future research needs to be performed to
assess the relevance of those metabolites in host physiol-
o g yh o m e o s t a s i s ,ak e yq u e s t i o nb e i n g :a r et h e r eo n l y
markers or actors of the interactions between diet, host,
and gut microbes?
Key words : gut microbiota, obesity, prebiotics, inflam-
mation, gut peptides.
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